1. Home
  2. HUSA vs MEIP Comparison

HUSA vs MEIP Comparison

Compare HUSA & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUSA
  • MEIP
  • Stock Information
  • Founded
  • HUSA N/A
  • MEIP 2000
  • Country
  • HUSA United States
  • MEIP United States
  • Employees
  • HUSA N/A
  • MEIP N/A
  • Industry
  • HUSA Oil & Gas Production
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • HUSA Energy
  • MEIP Health Care
  • Exchange
  • HUSA Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • HUSA 16.6M
  • MEIP 13.3M
  • IPO Year
  • HUSA N/A
  • MEIP 2003
  • Fundamental
  • Price
  • HUSA $12.93
  • MEIP $2.80
  • Analyst Decision
  • HUSA
  • MEIP Hold
  • Analyst Count
  • HUSA 0
  • MEIP 1
  • Target Price
  • HUSA N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • HUSA 4.1M
  • MEIP 13.3K
  • Earning Date
  • HUSA 08-13-2025
  • MEIP 05-13-2025
  • Dividend Yield
  • HUSA N/A
  • MEIP N/A
  • EPS Growth
  • HUSA N/A
  • MEIP N/A
  • EPS
  • HUSA N/A
  • MEIP N/A
  • Revenue
  • HUSA $514,839.00
  • MEIP N/A
  • Revenue This Year
  • HUSA N/A
  • MEIP N/A
  • Revenue Next Year
  • HUSA N/A
  • MEIP N/A
  • P/E Ratio
  • HUSA N/A
  • MEIP N/A
  • Revenue Growth
  • HUSA N/A
  • MEIP 33.76
  • 52 Week Low
  • HUSA $3.85
  • MEIP $1.46
  • 52 Week High
  • HUSA $32.00
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • HUSA 55.21
  • MEIP 78.43
  • Support Level
  • HUSA $10.71
  • MEIP $2.21
  • Resistance Level
  • HUSA $25.56
  • MEIP $2.95
  • Average True Range (ATR)
  • HUSA 3.76
  • MEIP 0.15
  • MACD
  • HUSA 0.39
  • MEIP 0.05
  • Stochastic Oscillator
  • HUSA 42.08
  • MEIP 81.48

About HUSA Houston American Energy Corporation

Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. Its properties, and operations, are in the U.S. Permian Basin, the U.S. Gulf Coast region, particularly Louisiana, and the South American country of Colombia. Geographically, the company currently has operations in two geographical areas, the United States, from where it derives maximum revenue, and Colombia.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: